Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-25T22:38:14.223Z Has data issue: false hasContentIssue false
  • English
  • Français

Superoxide dismutase activity of serum IgG in acute illness and remission period of schizophrenia

Published online by Cambridge University Press:  01 September 2022

I. Mednova ,
L. Smirnova ,
A. Vasilieva ,
N. Krotenko ,
E. Dmitrieva ,
A. Semke  and
S. Ivanova
I. Mednova
Affiliation:
Tomsk National Research Medical Center of the Russian Academy of Sciences, Mental Health Research Institute, Tomsk, Russian Federation
L. Smirnova
Affiliation:
Tomsk National Research Medical Center of the Russian Academy of Sciences, Mental Health Research Institute, Tomsk, Russian Federation
A. Vasilieva
Affiliation:
Siberian State Medical University, Department Of Biomedicine, Tomsk, Russian Federation
N. Krotenko
Affiliation:
Tomsk National Research Medical Center of the Russian Academy of Sciences, Mental Health Research Institute, Tomsk, Russian Federation
E. Dmitrieva*
Affiliation:
Tomsk National Research Medical Center of the Russian Academy of Sciences, Mental Health Research Institute, Tomsk, Russian Federation
A. Semke
Affiliation:
Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Department Of Endogenous Disorders, Tomsk, Russian Federation
S. Ivanova
Affiliation:
Tomsk National Research Medical Center of the Russian Academy of Sciences, Mental Health Research Institute, Tomsk, Russian Federation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

According to recent research violations of the oxidative-antioxidant balance may play an important role in the pathogenesis of schizophrenia, by changing generate, conduct and reproduce a nerve impulse. Antibodies with oxidoreductase activity may be involved in protection against oxidative stress in schizophrenia.

Objectives

The study was to compare the superoxide dismutase (SOD) activity of IgG in patients with acute schizophrenia and during remission.

Methods

The study included 20 patients with acute schizophrenia (mean PANSS total score 94,3±14), 18 people with schizophrenia during remission (mean PANSS total score 54,7±9), and 10 healthy individuals. All participants signed informed consent for the research. Isolation of IgG from blood serum was performed using affinity chromatography on Protein-G-Sepharose columns. The homogeneity of the substances is confirmed by the SDS PAGE method. SOD activity of IgG was carried out spectrophotometrically. Statistical processing was conducted with Statistica v.10.

Results

IgG of schizophrenia patients and healthy individuals have a SOD activity and studied activity is proved to be antibodies intrinsic property. The activity of antibodies in acute schizophrenia was 1.7 times higher than in healthy individuals (p<0.05). In patients with schizophrenia during remission SOD activity of IgG was 2.4 times higher than in healthy individuals (p<0.05).

Conclusions

We can assume that in the conditions of oppression antioxidant activity in schizophrenia patients, antibodies partially take over the function of protecting the body from patients with generalized oxidative stress. This work is supported by the Russian Scientific Foundation, grant # 18-15-00053P.

Disclosure

No significant relationships.

Keywords

oxidative stressschizophreniaIgG
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S286 - S287
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.